VANCOUVER, BC, June 10, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has filed additional provisional patents that utilize various psilocybin analogs to target clinical depression. Major Depressive Disorder (“MDD”) is a common and…


Previous articleFilament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update
Next articlePharmaTher Provides Research and Development Update and Milestones for 2021